Novo Nordisk's phase 2 trial of investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes
Novo Nordisk has unveiled striking Phase 2 trial results for its investigational drug, zenagamtide (also known as amycretin), showcasing significant reductions in HbA1C and an impressive average weight loss of up to 14.6% in adults with type 2 diabetes. Presented at the American Diabetes Association's 2026 Scientific Sessions, these findings position zenagamtide, a first-in-class unimolecular peptide agonist targeting both GLP-1 and amylin receptors, as a formidable contender in the rapidly expanding cardiometabolic therapeutic landscape.















.jpg)


